Home › NDC Lookup › Ingredients › Calcium Polycarbophil › 70000-0067-01
⚪image loading
(from DailyMed)

Calcium Polycarbophil 625 mg Tablet, Film Coated, 250-count

by LEADER/ Cardinal Health 110, Inc. · 250 TABLET, FILM COATED in 1 BOTTLE (70000-0067-1)
NDC 70000-0067-01
🏷️ FDA NDC (as labeled) 70000-0067-1 billing pads the package segment with a zero
OTC On market Non-controlled
🗂️ Data synced Jul 24, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

This page is curated, coded, and maintained by

Compiled from public FDA, CMS, DailyMed, NADAC, and related drug data sources. Editorial policy

🆔 Identity & classification

FDA NDC (as labeled) 70000-0067-1
Product NDC 70000-0067
11-digit billing NDC 70000006701
NCPDP billing unit EA — each (per item)
RxCUI 308934
UNII 8F049NKY49
UPC 0096295140279
Application # M007
SPL Set ID b4637e18-c65f-0e81-e053-2a95a90a2284
DEA schedule Non-controlled
Marketing category OTC MONOGRAPH DRUG
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 2020-11-18
Route ORAL
Dosage form TABLET, FILM COATED
Substance CALCIUM POLYCARBOPHIL
GPI-14 46300020100310
GPI class Fiber Laxative + Calcium
GCN Seq No 003065
GCN 08342
HICL code 001346
Ingredient (HICL) Calcium Polycarbophil
HIC1 code D
Therapeutic class — broad (HIC1) Biliary System/Gastro-Intestinal System
HIC2 code D6
Therapeutic class — intermediate (HIC2) Drugs Acting Principally On The Colon
HIC3 code D6S
Therapeutic class — specific (HIC3) Laxatives And Cathartics
AHFS code 56:12.00.00
AHFS class Cathartics And Laxatives
FDB label name FIBER LAXATIVE 625 MG CAPLET
FDB brand name Fiber Laxative
Legend status O — Over-the-counter (OTC) drug or device
Why two NDCs? The FDA registers this code as 70000-0067-1 — a 5-4-1 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the package segment → 70000-0067-01. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

🏷️ RxNorm drug class

This medicine belongs to the Bulk-forming laxatives class.

Drug family (ATC) Bulk-forming laxatives
Where does this data come from?
Therapeutic classes from RxNorm RxClass (U.S. National Library of Medicine) — Established Pharmacologic Class (FDA), ATC drug family (WHO) and mechanism of action, matched by this product’s RxCUI.

🏭 Manufacturer & labeler

LabelerLEADER/ Cardinal Health 110, Inc.
FDA applicationM007 (OTC MONOGRAPH DRUG)
Labeler code70000
First marketedNov 2020
Product typeHuman Otc Drug
Portfolio38 products on file
The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

🩺 Clinical

Label name FIBER LAXATIVE 625 MG CAPLET Ingredient Calcium Polycarbophil
🧪 What is this product?

This is an over-the-counter oral tablet containing calcium polycarbophil, a bulk-forming agent. Calcium polycarbophil is typically used to relieve constipation by absorbing water in the intestines and increasing stool bulk, which helps promote bowel movements. The tablet is film-coated for easier swallowing. This product is marketed under the FDA's OTC monograph rules for laxatives and stool softeners.

Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

🧪 Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

Loading inactive ingredients from the official FDA label in the background. No external source is being called by this page request.
Where does this data come from?
Source: official FDA Structured Product Labeling (SPL) via DailyMed and the openFDA label index. Structured IACT rows and label-wide narrative are kept separate; availability and product-level specificity depend on the submitted label.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

💲 Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer eaPer package
Retail pharmacies payNADAC · weekly $0.058 $14.60 / 250 tablets
Medicaid paysCMS SDUD · 12 mo $0.1624 $40.60 / 250 tablets
Medicare drug plans payPart D · quarterly No Part D plan price is available for this NDC in our data.
NADAC price history (per ea) — tap or hover for the price & month
Dec 2023 Dec 2025 Apr 2026 Aug 2026 $0.065 $0.058
▼ Down 8% over the last 12 months.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

🔁 Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Fiber Lax 625 mg 00536-4306-05 Rugby 500 tablets $0.058 — Availability likely —
Fiber Tabs 625 mg 00904-2500-91 Major 90 tablets $0.058 — Availability likely —
Calcium Polycarbophil 625 mgthis 70000-0067-01 LEADER/ 250 tablets $0.058 — Availability likely —
Foster and Thrive Fiber Laxative 147 625 mg 70677-1083-01 Strategic 90 tablets $0.058 — Availability likely —
Fiber caplets 147 625 mg 83324-0131-90 Chain 90 tablets $0.058 — Availability likely —
Walgreen Fiber Lax 625 mg 00363-0120-14 WALGREENS 140 tablets — — FDA listed —
up and up fiber therapy 625 mg 11673-0620-90 Target 140 tablets — — FDA listed —
Rite Aid Fiber Caplets 625 mg 11822-2025-00 RITE 250 tablets — — FDA listed —
Fiber Caplets 625 mg 21130-0021-40 SAFEWAY 140 tablets — — FDA listed —
Good Neighbor Pharmacy Fiber-Caps Fiber Laxative Stimulant Free 625 mg 24385-0125-27 Amerisourcebergen 90 capsules — — FDA listed —
Fiber Caplets 625 mg 30142-0132-14 THE 140 tablets — — FDA listed —
Fiber Laxative 625 mg 36800-0465-27 Topco 90 tablets — — FDA listed —
Fiber Laxative 625 mg 41163-0147-94 UNITED 140 tablets — — FDA listed —
Publix 625 mg 41415-0021-90 PUBLIX 90 tablets — — FDA listed —
Fiber Therapy 625 mg 49035-0147-94 Wal-Mart 140 tablets — — FDA listed —
Goodsense Fiber laxative 147 625 mg 50804-0147-94 GoodSense 140 tablets — — FDA listed —
Fiber Caps 625 mg 53041-0147-27 Guardian 90 tablets — — FDA listed —
Fiber laxative 625 mg 53943-0147-27 Discount 90 tablets — — FDA listed —
Fiber Laxative 625 mg 54257-0379-07 Magno-Humphries, 90 tablets — — FDA listed —
Fiber Laxative 625 mg 54257-0479-07 Magno-Humphries, 90 tablets — — FDA listed —
Fiber Lax 625 mg 55289-0949-30 PD-Rx 30 tablets — — FDA listed —
Fiber Laxative 625 mg 57896-0459-09 Geri-Care 90 tablets — — FDA listed —
Calcium Polycarbophil 625 mg 58624-5003-01 SHANDONG 90 tablets — — FDA listed —
Quality Choice 625 mg 63868-0530-90 QUALITY 90 tablets — — FDA listed —
Best Choice 625 mg 63941-0023-90 BEST 90 tablets — — FDA listed —
Premier Value 625 mg 68016-0220-25 PHARMACY 250 tablets — — FDA listed —
Calcium Polycarbophil 625 mg 69842-0846-02 CVS 250 tablets — — FDA listed —
Calcium Polycarbophil 625 mg 70369-0006-08 CITRAGEN 120 tablets — — FDA listed —
Amazon Fiber Caplets 625 mg 72288-0201-40 AMAZON.COM 140 tablets — — FDA listed —
Fiber Laxative Caplets 625 mg 77333-0120-50 Gendose 50 tablets — — FDA listed —
Meijer Fiber Caplets 625 mg 79481-1205-00 MEIJER 250 tablets — — FDA listed —
Fibercon 625 mg 80070-0500-14 Foundation 140 tablets — — FDA listed —
Quality Choice Fiber Caplets 625 mg 83324-0276-14 QUALITY 140 tablets — — FDA listed —
Equalactin Laxative 625 mg 69846-0000-26 NUMARK 24 tablets — — Discontinued —
Fibercon 625 mg 63029-0170-14 Medtech 140 tablets — — FDA listed —
About this product: other versions of the same ingredient, strength and form are listed above, least expensive first, with FDA equivalence ratings where available.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

⏳ Availability & generic status

🏛️
2020
On the market since
Nov 2020
📍
2026
Currently FDA-listed
6 years listed
🔒
·
No generic listed yet
brand only
ℹ️No FDA-approved generic found

We did not find an FDA-approved generic match for this exact strength, form and route.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

🗺️ Medicaid utilization & spend

📍 This exact package only: Medicaid data is reported per full 11-digit NDC — labeler, product and pack size — so every number here is for 70000-0067-01, not the drug overall. Other pack sizes report separately.
💊 Pharmacy benefit only: These are Medicaid outpatient pharmacy claims, billed by NDC. They exclude the medical benefit — clinic- or hospital-administered drugs billed under HCPCS J-codes — so drugs used mostly that way (e.g. Avastin, Lucentis, Keytruda) can look low or missing here. That’s expected, not an error.
📅 Q1 2025 – Q1 2026 · 5 quarters of data
ⓘ The newest quarter is usually incomplete when first published; states restate recent quarters in later CMS releases, so the latest figures typically revise upward. State coverage-policy changes can also shift quarter-to-quarter totals.
Prescriptions last 4 qtrs
2.6K
Units reimbursed last 4 qtrs
187.3K
Gross reimbursed last 4 qtrs
$30.4K
Avg / prescription
$11.76
Avg / unit
$0.1624
Latest quarter Q1 2026
681Rx
Medicaid pays / ea
$0.1624
gross reimbursed
vs
NADAC / ea
$0.0584
acquisition cost
=
Spread
+$0.1040
+178% vs cost
What Medicaid paid per ea (before rebates; includes the pharmacy’s dispensing fee) compared with NADAC — the average price pharmacies pay to buy the drug. A positive spread means Medicaid reimbursed more than the purchase price, before manufacturer rebates.
Fee-for-service vs managed care ⓘ
66% FFS 34% MCO
Fee-for-service · 1,709 Rx Managed care · 878 Rx
State Medicaid map
Alaska: no data reported AK Maine: no data reported ME Washington: no data reported WA Idaho: no data reported ID Montana: 484 units · 42.8 per 100k residents MT North Dakota: no data reported ND Minnesota: 2,202 units · 38.4 per 100k residents MN Wisconsin: no data reported WI Michigan: no data reported MI New York: 99,813 units · 510 per 100k residents NY Vermont: 594 units · 91.8 per 100k residents VT New Hampshire: no data reported NH Oregon: no data reported OR Nevada: no data reported NV Wyoming: no data reported WY South Dakota: no data reported SD Iowa: no data reported IA Illinois: no data reported IL Indiana: no data reported IN Ohio: 10,623 units · 90.1 per 100k residents OH Pennsylvania: 1,842 units · 14.2 per 100k residents PA New Jersey: 4,910 units · 52.9 per 100k residents NJ Massachusetts: 1,230 units · 17.6 per 100k residents MA California: 14,521 units · 37.3 per 100k residents CA Utah: no data reported UT Colorado: 617 units · 10.5 per 100k residents CO Nebraska: 3,808 units · 193 per 100k residents NE Missouri: no data reported MO Kentucky: 18,047 units · 399 per 100k residents KY West Virginia: no data reported WV Virginia: no data reported VA Maryland: no data reported MD Connecticut: 12,328 units · 341 per 100k residents CT Rhode Island: no data reported RI Arizona: 930 units · 12.5 per 100k residents AZ New Mexico: no data reported NM Kansas: 15,334 units · 522 per 100k residents KS Arkansas: no data reported AR Tennessee: no data reported TN North Carolina: no data reported NC South Carolina: no data reported SC Delaware: no data reported DE Oklahoma: no data reported OK Louisiana: no data reported LA Mississippi: no data reported MS Alabama: no data reported AL Georgia: no data reported GA D.C.: no data reported DC Hawaii: no data reported HI Texas: no data reported TX Florida: no data reported FL
Units reimbursed · per 100k residents
10.5522
gray = no data reported ⓘ
Colors are per 100,000 residents, so big states don’t automatically dominate. Tap or hover a state for its actual totals.
Tap or hover a state
…for its Medicaid breakdown
🏆 Top states by units · per 100k residents
1 Kansas 522 /100k
2 New York 510 /100k
3 Kentucky 399 /100k
4 Connecticut 341 /100k
5 Nebraska 193 /100k
6 Vermont 91.8 /100k
7 Ohio 90.1 /100k
8 New Jersey 52.9 /100k
National units — by quarter
💵 About the dollar figures: “reimbursed” is what Medicaid paid pharmacies before confidential manufacturer rebates, so the program’s real net cost is lower than these numbers. Fee-for-service and managed-care claims are combined unless split above. Source: CMS State Drug Utilization Data; per-100k rates use 2023 Census population estimates.

📦 Packaging — all sizes for this product

Package NDCDescription Marketing startStatus
70000-0067-01 You're viewing this 250 TABLET, FILM COATED in 1 BOTTLE (70000-0067-1) 2020-11-18 Active

📄 FDA label — Drug Facts FDA SPL

The complete FDA label for this product — the official Drug Facts labeling, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
🎯 Indications and Usage ⏱️ Dosage and Administration ⚠️ Warnings 🆘 Overdosage 🧪 Active Ingredient 🧪 Inactive Ingredients 🎯 Purpose
🎯 Indications and Usage 14 words ▾

Uses relieves occasional constipation (irregularity) generally produces bowel movement in 12 to 72 hours

⏱️ Dosage and Administration 83 words ▾

Directions take each dose of this product with a full glass of water (8oz.) or other fluid. Taking this product without enough liquid may cause choking. See choking warning. dosage will vary according to diet, exercise, previous laxative use or severity of constipation continued use for 1 to 3 days is normally required to provide full benefit adults and children 12 years of age and over 2 caplets, 1 to 4 times per day children under 12 years of age ask a doctor

⚠️ Warnings 198 words ▾

Warnings Choking: Taking this product without adequate fluid may cause it to swell and block your throat or esophagus and may cause choking. Do not take this product if you have difficulty in swallowing. If you experience chest pain, vomiting, or difficulty in swallowing or breathing after taking this product, seek immediate medical attention.

Ask a doctor before use if you have abdominal pain, nausea, or vomiting a sudden change in bowel habits that persists over a period of 2 weeks Ask a doctor or pharmacist before use if you are taking any other drug. Take this product two or more hours before or after other drugs. All laxatives may affect how other drugs work.

When using this product do not use for more than 7 days unless directed by a doctor do not take more than 8 caplets in a 24-hour period unless directed by a doctor Stop use and ask a doctor if you fail to have a bowel movement after use or have rectal bleeding. These could be signs of a serious condition. Keep out of reach of children.

In case of overdose, get medical help or contact a Poison Control Center (1-800-222-1222) right away.

🆘 Overdosage 16 words ▾

In case of overdose, get medical help or contact a Poison Control Center (1-800-222-1222) right away.

🧪 Active Ingredient 16 words ▾

Drug Facts Active ingredient (in each caplet) Calcium polycarbophil 625 mg (equivalent to polycarbophil 500 mg)

🧪 Inactive Ingredients 21 words ▾

Inactive ingredients caramel, crospovidone, hypromellose, magnesium stearate, microcrystalline cellulose, mineral oil, polyethylene glycol, silicon dioxide, sodium lauryl sulfate, stearic acid, talc.

🎯 Purpose 3 words ▾

Purpose Bulk-forming laxative

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗
← 70000-0066-01 · LEADER/ 70000-0072-01 · CARDINAL →
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.